Table 7

Antitumor activity of ZD1839 and platinum compounds given alone or in combination against human prostate tumors xenografted to nude mice

Two experiments of four mice/group.

TumorDrug compoundaAverage weight change (%)Average tumor diameterb,c (mm ± SE)Change in tumor volumeb,c (mm3)Tumor-free mice (no./total)
TSU-PR1112.1 ± 2+8860 /8
ZD1839 (75)−29.7 ± 1+4950 /8
CBCDA (50)−18.2 ± 1+2470 /8
ZD1839+ CBCDA−25.7 ± 1+550 /8
PC-319.5 ± 2+4490 /8
ZD1839 (75)−17.4 ± 1+2080 /8
CBCDA (50)−15.8 ± 1+620 /8
ZD1839+ CBCDA−33.7 ± 1−212 /8d
  • a ZD1839 given (qd × 5) × 2 and platinums given every 3–4 days × 4.

  • b Initial tumor mass was 50–65 mg (4.8 ± 0.2 mm diameter).

  • c Measurements made 2–3 days after dose.

  • d Tumor regrowth in one of two mice (PC-3) 21 days after treatment.